Lisa Salvatore (@LisaSalvy) profile picture

Lisa Salvatore

@LisaSalvy

Medical Oncologist #GIcancer #AIRCResearcher 🎀 Alice’s mum ☀️🌈🌊🍻🤸‍♂️🎭🎼🏝📖 lover ❤️

 Rome
Joined February 2012
  • Tweets78
  • Following194
  • Followers131
46Media
Photo by Lisa Salvatore (@LisaSalvy)Photo by Lisa Salvatore (@LisaSalvy)
Across the sotorasib/panitumumab and investigator’s choice arms, the distribution of genes showing emergent alterations was comparable, with a mean of 5 genes harboring emergent mutations in each patient (P = .99). #gicsm #ASCO25 | @ASCO @LisaSalvy cancernetwork.com/view/genom…
Genomic Alterations May Cause Resistance to Sotorasib KRAS G12C+ CRC Combo | CancerNetwork

Genomic Alterations May Cause Resistance to Sotorasib KRAS G12C+ CRC Combo | CancerNetwork

Emergent alteration patterns were similarly diverse across treatment arms in the phase 3 CodeBreaK 300 study.

cancernetwork.com
1
1
260
Comparison of first-line CT regimens in unresectable locally advanced or metastatic #pancsm : a systematic review and Bayesian network meta-analysis ⁦@TheLancetOncol⁩ super comprehensive work, congrats ⁦@LisaSalvy⁩ ‼️ thelancet.com/journals/lanon…
Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic...

Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic...

Our findings suggest that NALIRIFOX and FOLFIRINOX should be the preferred options for patients who can tolerate these regimens, with gemcitabine plus nab-paclitaxel remaining a viable alternative,...

thelancet.com
1
8
21
1,217
Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis. Thanks to all my team. Good job guys! ⁦@TheLancet⁩ ⁦@Unicatt⁩ thelancet.com/journals/lanon…
Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic...

Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic...

Our findings suggest that NALIRIFOX and FOLFIRINOX should be the preferred options for patients who can tolerate these regimens, with gemcitabine plus nab-paclitaxel remaining a viable alternative,...

thelancet.com
1
1
12
389
Replying to @FilippoPietran4
@FilippoPietran4 @ChiaraCrem1 @LisaSalvy @myESMO #ESMO23 – at Madrid, Spain
NEJM (@NEJM) profile pictureNEJM
@NEJM23 Oct 2023
Original Article: Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C (CodeBreaK 300 phase 3 trial) nej.md/3M8Qw3k #ESMO23 #oncology
Progression-free Survival as Assessed by Blinded Independent Central Review (Intention-to-Treat Population)

ALT Progression-free Survival as Assessed by Blinded Independent Central Review (Intention-to-Treat Population)

2
2
424
Replying to @FilippoPietran4
@FilippoPietran4 presenting at #ESMO23 CodeBreaK 300 phase 3 study of sotorasib plus panitumumab versus standard care in patients with chemorefractory KRAS-mutated #CRC @ChiaraCrem1 @LisaSalvy @myESMO @NEJM – at Madrid, Spain
Image from Lorenza Rimassa (@LorenzaRimassa)
Image from Lorenza Rimassa (@LorenzaRimassa)
Image from Lorenza Rimassa (@LorenzaRimassa)
Image from Lorenza Rimassa (@LorenzaRimassa)
5
13
877
Lisa Salvatore retweeted
Carmelo Pozzo (@CarmeloPozzo) profile picture
Carmelo Pozzo@CarmeloPozzo22 Oct 2023
Gemelli Rome Oncology Team at #ESMO23 in Madrid #ESMO #Gemelli
Image from Carmelo Pozzo (@CarmeloPozzo)
3
10
26
1,020
We are culminating our 🇮🇹National Event with a roundtable session engaging experts and policymakers to reflect upon the key themes we tackled today. #PazienteAlCentro #DigestiveCancers #DigestiveHealth
Image from Digestive Cancers Europe (@dice_europe)
Image from Digestive Cancers Europe (@dice_europe)
Image from Digestive Cancers Europe (@dice_europe)
3
7
211
Lisa Salvatore retweeted
AIOM (@AIOMtweet) profile picture
AIOM@AIOMtweet22 Aug 2023
Lisa Salvatore (@LisaSalvy) su AIOM Tv per parlare di tumori gastrointestinali. Le evidenze dall’ASCO23: youtu.be/ptv1z-WS8Vo #aiomtv #oncologia #intervista
1
3
367
CRC oral session on the updated and OS results of the AtezoTRIBE study by GONO. Again confirmation that Immunoscore IC is able to select patients with immunesensitive pMMR/MSS mCRC and PFS/OS benefit from the addition of atezo to FOLFOXIRI/bev. @carlottanto1 @ChiaraCrem1
Image from GONO Foundation (@FoundationGono)
10
1
17
2,985
Lisa Salvatore retweeted
Arndt Vogel (@ArndtVogel) profile picture
Arndt Vogel
@ArndtVogel4 Jun 2023
🔥 AtezoTRIBE: OS data for FOLFOXIRI + Bev vs FOLFOXIRI + AtezoBev in 1st line #mCRC #ASCO23 🔎RAS mut 71%/74%, BRAF mut 14%/8, TMBhigh 10%/12%, high IS IC 32%/32% 👉mPFS 11.5 vs 13.1 mo 👉mPFS2: 19.9 vs 22.6 mo 👉mOS 27.2 vs 33 mo ✅ Benefit for IS IC-high and/or TMB high pMMR mCRC @myESMO @OncoAlert
Image from Arndt Vogel (@ArndtVogel)
Image from Arndt Vogel (@ArndtVogel)
Image from Arndt Vogel (@ArndtVogel)
Image from Arndt Vogel (@ArndtVogel)
40
82
9,040
4th may: First day of our meeting in a wonderful location, inspiring talks by @elena_elez @JenSeligmann and after dinner party. Science is also about friendship and networking!
Image from GONO Foundation (@FoundationGono)
Image from GONO Foundation (@FoundationGono)
Image from GONO Foundation (@FoundationGono)
Image from GONO Foundation (@FoundationGono)
1
5
1
26
7,103
Lisa Salvatore retweeted
Arndt Vogel (@ArndtVogel) profile picture
Arndt Vogel
@ArndtVogel16 Apr 2023
🔥Hot of the press: Pembrolizumab in combination with GemCis compared with GemCis in biliary tract cancer @TheLancet 👇doi.org/10.1016/S0140-6736(2… 🔎KEYNOTE-966🗺️phs-III 1069 pts 💪Significant OS ⬆️ ✅ICI = integral part of systemic 💊 in BTC @myESMO @CcaEns @EASLedu #livertwitter
Image from Arndt Vogel (@ArndtVogel)
16
110
24
277
101,272
A great pleasure to speak about #Immunotherapy in #larc at the #gemcad IX Symposium in Valencia. Thanks @Ja_Capdevila for this great opportunity
1
1
4
1,066
Huge compliments 🏅 @LisaSalvy for receiving @AIRC_it support for her research project on #rectalcancer. Big researcher, mummy, and friend!
Image from Roberto Iacovelli (@DrIacovelli)
2
1
17
CRC educational session at #Aiom22… no gender balance! Well done ⁦@AIOMtweet⁩ ⁦@lonardi_sara⁩ ⁦@LisaSalvy⁩
Image from Chiara Cremolini (@ChiaraCrem1)
3
38
Lisa Salvatore retweeted
AISP (@AISP_Pancreas) profile picture
AISP@AISP_Pancreas8 Apr 2022
Al via il corso di alfabetizzazione per l'oncologo! Seguici per una giornata di discussione sul tumore del pancreas! Per oncologi... E non solo! 🤩
Image from AISP (@AISP_Pancreas)
5
1
14
✳️In clinical practice, Reinduction of an Anti-EGFR-based First-line Regimen after off-treatment progression may be chosen. However, few data support this reasonable practice. ✌🏼Now out in @OncJournal our propensity score based analysis of Valentino Study academic.oup.com/oncolo/adva…
1
11
1
20
Great job @LisaSalvy!
Filippo Pietrantonio (@FilippoPietran4) profile pictureFilippo Pietrantonio@FilippoPietran45 Jun 2021
CRC PD Session Lisa Salvatore presenting the results of AVANA study by GONO Foundation: avelumab plus cape-chemoradiation induced 23% pCR in LARC. Happy to have contributed to this study :)
Image from Filippo Pietrantonio (@FilippoPietran4)
1
3
CRC PD Session Lisa Salvatore presenting the results of AVANA study by GONO Foundation: avelumab plus cape-chemoradiation induced 23% pCR in LARC. Happy to have contributed to this study :)
Image from Filippo Pietrantonio (@FilippoPietran4)
2
4
2
15
@LisaSalvy
1
3
Load more